ZANTAC 75 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zantac 75, and when can generic versions of Zantac 75 launch?
Zantac 75 is a drug marketed by Chattem Sanofi and is included in two NDAs.
The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 75
A generic version of ZANTAC 75 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZANTAC 75?
- What are the global sales for ZANTAC 75?
- What is Average Wholesale Price for ZANTAC 75?
Summary for ZANTAC 75
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 22 |
| Patent Applications: | 2,243 |
| What excipients (inactive ingredients) are in ZANTAC 75? | ZANTAC 75 excipients list |
| DailyMed Link: | ZANTAC 75 at DailyMed |
Recent Clinical Trials for ZANTAC 75
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Food and Drug Administration (FDA) | Phase 1 |
| Spaulding Clinical Research LLC | Phase 1 |
| Nova Scotia Health Authority | Phase 4 |
US Patents and Regulatory Information for ZANTAC 75
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET, EFFERVESCENT;ORAL | 020745-001 | Feb 26, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC 75
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC 75
See the table below for patents covering ZANTAC 75 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 7595581 | ⤷ Sign Up | |
| New Zealand | 198522 | FORM 2 RANITIDINE HYDROCHLORIDE:THE HYDROCHLORIC SALT OF N-(2-(((5-(DIMETHYLAMINO)METHYL)-2-FURANYL)METHYL)-THIO)ETHYL-N1-METHYL-2-NITRO-1,1-ETHENEDIAMINE | ⤷ Sign Up |
| Finland | 80687 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
